-
Hyderabad: The Republic of Vietnam will receive two lakh doses of Bharat Biotech’s Covaxin. This donation represents a goodwill gesture to provide access to the company’s WHO approved, indigenously developed Covaxin to fight the Covid-19 pandemic across borders. Covaxin has received emergency use listing in Vietnam. Suchitra Ella, joint managing director of Bharat Biotech, revealed this at […]
-
Hyderabad: Hyderabad-based Covid-19 vaccine (Covaxin) maker Bharat Biotech on Monday said the company has commenced the exports of the vaccine. “Long pending export orders have been executed during November, to be further expanded during the following months. With the number of countries that have granted emergency use approvals for Covaxin increasing, exports to additional countries […]
-
Hyderabad: Covaxin, the first indigenous Covid vaccine developed and manufactured by Hyderabad-based Bharat Biotech, continues to receive recognition from various quarters. The vaccine recently came in for praise from Dr Francis H Collins, Director of National Institutes of Health (NIH), primary agency in the United States for public health research. Following the publishing of interim […]
-
New Delhi: The World Health Organisation (WHO) on Wednesday granted Emergency Use Listing approval to India’s indigenously-developed Covid vaccine, Bharat Biotech’s Covaxin. The global health group’s Technical Advisory Group (TAG) issued the final decision.The WHO, in a tweet, said: “WHO has granted emergency use listing (EUL) to Covaxin, developed by Bharat Biotech, adding to a […]
-
Hyderabad: The shelf life of Hyderabad-based Bharat Biotech’s Covid-19 vaccine, Covaxin, has been extended to 12 months from the present nine months by the Central Drugs Standard Control Organisation (CDSCO). “The CDSCO has approved the extension of shelf life of Covaxin up to 12 months, from the date of manufacture. This approval of shelf life […]
-
Hailing the decision, the Indian High Commission in Guyana said that it is an important step forward in the post Covid partnership between both the countries.
-
Ocugen, the US partner of Bharat Biotech, has submitted an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to evaluate the Covid-19 vaccine candidate, BBV152, known as Covaxin outside the United States. The phase 3 trial proposed in the IND is designed to establish whether the immune response experienced by […]
-
Hyderabad: The state health authorities here have said that are expecting a Covid vaccine for children to be available in the coming two to three weeks. The authorities said that under the guidance of the Ministry of Health and Welfare (MOHFW), extensive ground work is underway in Telangana to start vaccinating children, as and when […]
-
Hyderabad: The World Health Organization (WHO) tweeted on Tuesday that WHO and an independent group of experts will meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing (EUL) to Covaxin. Covaxin manufacturer, Bharat Biotech, has been submitting data to WHO on a rolling […]
-
MoHFW may approve Covid vaccine this month for those aged between 12 years and 18 years
-
Hyderabad: Bharat Biotech completed the Phase 2/3 trials of Covid-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella said on Tuesday here. Speaking to reporters, he said Covaxin […]
-
Union minister of Health and Family Welfare Mansukh Mandaviya formally launched the Covaxin batches. Dr Krishna Ella, CMD, Bharat Biotech and Suchitra Ella, joint managing director, Bharat Biotech were also present at the launch.
-
IVI is advancing clinical development of BBV87 through a phase II/III randomised, controlled trial to evaluate the safety and immunogenicity of a 2-dose regimen of BBV87 chikungunya vaccine
-
Nod for Zydus Cadila'd Covid vaccine for children will help India ramp up its vaccination programme quickly
-
Output of Covaxin drug substance will be adequate for 3 to 4 million doses a month and from December it will increase to 10 million doses a month
-
The approval has been received from the National Institute of Pharmacy and Nutrition, Hungary, certifying the GMP for the manufacture of Covaxin.
-
More than half of the adult population has yet to receive even a single dose, despite a slight improvement in coverage in July
-
The vaccine is used for the prevention of rotavirus infection, which is prevalent in infants and young children
-
The company had supplied about four billion doses to about 125 countries and will continue to ramp up production at its four plants in the country, said Suchitra Ella, co-founder of Bharat Biotech
-
Efficacy data also demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant, the company said in a statement while announcing its phase 3 data analysis.
